SpectrumX Partners With Leading UK Specials Group to Accelerate Production of Anti-Pathogenic Drug for Clinical Trials

  • Partner will manufacture SpectrumX’s SPC-069-based product for clinical trials, shortening the path to commercialisation
  • New medical product is a forthcoming ground-breaking treatment for respiratory infections, including COVID-19, influenza, the common cold and others

LONDON--()--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces its partnership with a leading UK-based specials contract manufacturing group with global reach to advance the production of its ground-breaking anti-pathogenic medicine for use in its planned Phase I clinical trials. This group has unparalleled experience working with pharmaceutical companies in MHRA-compliant medicine production.

SpectrumX plans to use its partner’s Good Manufacturing Practice (GMP)-certified facility to produce SPX-001, the medical product based on the SPC-069 drug substance, for clinical trials. SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties. SpectrumX will continue to produce its proprietary HOCl chemistry, essential to SPX-001’s success, at its production facility in Knutsford.

The Medicines and Healthcare products Regulatory Agency (MHRA) requires that drugs for trials must be manufactured in a GMP approved facility. SpectrumX’s chosen partner is a leader in contract drug development and manufacturing services and possesses the expertise required to streamline the roll-out of the production of the SPX-001 investigational medicinal product for use in SpectrumX’s clinical trials programme. By partnering in this way, SpectrumX will be well-prepared for an upcoming MHRA scientific advice meeting.

Damien Hancox, Chief Executive Officer of SpectrumX, said: “I am pleased to announce our partnership with an established leader in the manufacture and production of drugs for clinical trials. This partnership will hasten the process of getting SPX-001, our SPC-069-based medical product, to clinical trials and may provide us an opportunity to commercialise our lead pharmaceutical product in a shorter time frame.”

- ENDS -

About SpectrumX

SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market a ground-breaking respiratory therapy and the roll-out of the most powerful hand sanitiser in the world to the NHS and other healthcare clients. Both products utilise unique patent pending HOCl formulations. HOCl is naturally occurring in human’s white blood cells and is a key contributor to mankind’s evolution and protection over millions of years. It is human safe whilst also being the most effective disinfectant known to mankind. For more on SpectrumX visit www.spectrumx.com.

Contacts

Luther Pendragon
Jeff Segvich/Amy Stupavsky
spectrumx@luther.co.uk
+44 (0)20 7618 9100

Contacts

Luther Pendragon
Jeff Segvich/Amy Stupavsky
spectrumx@luther.co.uk
+44 (0)20 7618 9100